AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase I study titled A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours. The study aims to understand how rifampicin, a known drug, affects the pharmacokinetics of cediranib, an experimental treatment, in patients with advanced solid tumors. This research is significant as it could influence future treatment protocols for cancer patients.
The study involves administering cediranib alone, then in combination with rifampicin, and finally reverting to cediranib alone. Cediranib is given at 45 mg daily, with rifampicin added at 600 mg daily during the second phase of the treatment cycle. The goal is to assess how these drugs interact when used together.
This is an open-label, non-randomized, single-group study primarily focused on treatment. There is no masking involved, meaning both researchers and participants know which treatments are being administered.
The study began on September 9, 2008, with its last update submitted on July 22, 2025. These dates are crucial as they mark the study’s progression and the latest information available to stakeholders.
The ongoing study could impact AstraZeneca’s stock performance and investor sentiment, especially if results show significant benefits of combining cediranib with rifampicin. This could position AstraZeneca favorably against competitors in the oncology market.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.